| タイトル |
Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
|
| 著者 |
M. Shiraki
Fukunaga M.
Kishimoto H.
Hagino H.
Sone T.
Nakano T.
Ito M.
Yoshikawa H.
Minamida T.
Tsuruya Y.
Nakamura T.
|
| 収録物名 |
OSTEOPOROSIS INTERNATIONAL
|
| 巻 | 30 |
| 号 | 11 |
| 開始ページ | 2321 |
| 終了ページ | 2331 |
| 収録物識別子 |
ISSN 0937-941X
EISSN 1433-2965
|
| 主題 |
Teriparatide; Osteoporosis; Bone mineral density; Safety; Twice-weekly; Randomized controlled trial
|
| 言語 |
英語
|
| 資源タイプ | 学術雑誌論文 |
| 出版者 |
SPRINGER LONDON LTD
|
| 発行日 | 2019-11 |
| アクセス権 | メタデータのみ |
| 関連情報 |
[DOI] 10.1007/s00198-019-05111-6
[PMID] 31392401
|
| 備考 | The study was sponsored and funded by the Asahi Kasei Pharma Corporation, Tokyo, Japan. The sponsor had responsibility for quality control. The corresponding author had full access to all of the data in the study and had responsibility for the decision to submit for publication.; The study was jointly designed by the authors and the sponsor, Asahi Kasei Pharma Corporation. The authors discussed the interpretation of the data and the conclusions of the manuscript with the sponsor. Data analyses for publication were the responsibilities of the sponsor. ToS has received research grants from Astellas Pharma, Eisai, Daiichi-Sankyo, Chugai Pharmaceutical, and Eli Lilly Japan, as well as consulting and/or lecture fees from Asahi Kasei Pharma and Daiichi-Sankyo. MS has received consulting fees from Asahi Kasei Pharma, Chugai Pharmaceutical and Teijin Pharma. HK has received consulting fees from Asahi Kasei Pharma, Chugai Pharmaceutical, Daiichi-Sankyo and EA Pharma. HH has received consulting fees for this study from Asahi Kasei Pharma and lecture fees or grants outside the submitted work from Asahi Kasei Pharma, Astellas Pharma, Chugai Pharmaceutical, Eisai, Eli Lilly Japan, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Ono Pharmaceutical, Pfizer, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, Teijin Pharma and Daiichi-Sankyo. TeS has received research grants from Asahi Kasei Pharma, Astellas Pharma, Kissei Pharmaceutical, Pfizer, Taisho Toyama Pharmaceutical and Takeda Pharmaceutical. TeN has received consulting fees from Asahi Kasei Pharma. MI has received research grants from Asahi Kasei Pharma, Astellas Pharma, Chugai Pharmaceutical and Daiichi-Sankyo. TM is an employee of Asahi Kasei Pharma. YT is an employee of Asahi Kasei Pharma. ToN has received consulting fees from Asahi Kasei Pharma and Chugai Pharmaceutical, and speaker fees from Daiichi-Sankyo and Taisho Toyama Pharmaceutical. |
